CONFLICT OF INTEREST
Bipolar Disorder
DISORDERS
HN is a full‐time employee of Sumitomo Pharma Co., Ltd. Other authors declare that there are no conflicts of interest in relation to this study. We declare the following interests within the past 3 years: TKishi, TKato, and NI. TKishi has received speaker's honoraria from Sumitomo, Eisai, Janssen, Otsuka, Meiji, Tanabe‐Mitsubishi, Viatris, and Takeda and research grants from Eisai, the Japanese Ministry of Health, Labour and Welfare, Grant‐in‐Aid for Scientific Research, and Japan Agency for Medical Research and Development. TKato reports grants and personal fees from Sumitomo Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., Shionogi & Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Eisai Co., Ltd., personal fees from Taisho Pharma Co., Ltd., Mochida Pharmaceutical Co., Janssen Pharmaceutical K.K., Janssen Asia Pacific, Yoshitomiyakuhin, MSD K.K., Kyowa Pharmaceutical Industry Co., Ltd., Taisho Pharmaceutical Co., Ltd., Teijin Pharma, Viatris, Mylan N.V., outside the submitted work. He is an Editor‐in‐Chief of Psychiatry and Clinical Neurosciences (Editor in Chief), and a chair of Bipolar Disorder Committee and a member of Treatment Guidelines Committee of the Japanese Society for Mood Disorders. NI has received speaker's honoraria from Sumitomo, Eisai, Eli Lilly, Janssen, Takeda, Meiji, Tanabe‐Mitsubishi, Otsuka, and Viatris and research grants from Daiichi Sankyo, Eisai, Takeda, Sumitomo, Meiji, Tanabe‐Mitsubishi, and Otsuka.